Essential Pharma is planning to discontinue production of first-line bipolar disorder treatment Priadel next year, leaving a range of more expensive alternatives on the market.

 
The Royal Pharmaceutical Society (RPS) has said it is ”deeply concerned” and warned of the “huge extra cost” to the NHS after a manufacturer announced plans to discontinue production of one of its branded lithium carbonate products.

In August 2020, Essential Pharma said it would be discontinuing production of Priadel 200mg and 400mg — used as a first-line treatment for bipolar disorder — in April 2021 “due to restrictions on permitted pricing”, making the product “no longer viable”.

Click here to read full article https://www.pharmaceutical-journal.com/news-and-analysis/news/rps-warns-of-huge-extra-cost-to-nhs-after-bipolar-drug-withdrawn/20208308.article